Neonatal AI-Based Early Warning System for Late-Onset Sepsis and Necrotizing Enterocolitis in the NICU: Assessment of Response and Effectiveness
Key facts
- Who runs it
- University Hospital, Antwerp
- Where
- Belgium and Netherlands3 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 500 people, planned
- Started
- 9 Nov 2026
- Expected to end
- 31 Mar 2028
- Type of study
- Interventional
- Treatments tested
- Intellicens Neo software
- Record updated
- 12 November 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Neonates born below a gestational age of 32 weeks
- Admitted to the NICU
- Written informed consent
Who cannot take part
- Severe congenital malformations
- Admission for palliative care
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to evaluate the Intellicens software, an artificial intelligence (AI)-based early warning system designed to help doctors and nurses detect serious complications in premature babies at an early stage. These complications include bloodstream infections (sepsis) and necrotizing enterocolitis (NEC), a serious condition affecting the intestines.
Read full original descriptionShow less
The study will involve babies born before 32 weeks of pregnancy who are admitted to the Neonatal Intensive Care Unit (NICU). The Intellicens Neo model analyses routinely collected medical data, such as heart rate, to identify patterns that may indicate an increased risk of sepsis or NEC and generate an early warning for healthcare professionals. The treating doctor remains responsible for deciding whether further examinations or treatment are needed.
The software has previously been tested using data from babies who had already been discharged from hospital, with promising results. This study will evaluate how well the software performs in real-life clinical practice during the hospital stay.
The group in the trial
- Intellicens Neo implementation groupTreatment being tested
Preterm infants born at less than 32 weeks of gestational age admitted to participating neonatal intensive care units (NICUs) after implementation of Intellicens Neo. The software generates visual alerts for potential late-onset sepsis (LOS) and necrotizing enterocolitis (NEC). Alerts are visible to the clinical care team, while clinical assessment and treatment decisions remain at the discretion of the treating clinicians. Study outcomes will be compared with a historical pre-implementation dataset.
Treatment: Intellicens Neo software
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Neonatal AI-Based Early Warning System for Late-Onset Sepsis and Necrotizing Enterocolitis in the NICU: Assessment of Response and Effectiveness in a Post-Implementation Prospective Study With Pre-Implementation Historical Comparison
- Record updated
- 12 November 2026